Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
|Videos|May 1, 2013
Patrick Gleason of Prime Therapeutics on Pharmacogenomic Testing
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Advertisement
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Advertisement
Related to this article
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association, discusses pharmacists’ role in diabetes and CKD care at ASN Kidney Week 2026.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
4
Full IDWeek Data Highlights 31-Valent Pneumococcal Conjugate Vaccine Candidate in Adults
5